MAZE Stock Analysis: Buy, Sell, or Hold?
MAZE - Maze Therapeutics, Inc. Common Stock
$28.80
-0.25 (-0.86%)
▼
5d:
-9.18%
30d:
-38.04%
90d:
-30.49%
HOLD
LOW Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: May 13, 2026
Get Alerted When MAZE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: MAZE shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: MAZE shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: MAZE is currently trading at $28.80, which is considered oversold relative to its 30-day fair value range of $37.62 to $51.45.
Technical Outlook: Technically, MAZE is in a uptrend. The price is currently testing key support at $28.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $64.27 (+121.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, MAZE is in a uptrend. The price is currently testing key support at $28.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $64.27 (+121.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$37.62 -
$51.45
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 121.2% below Wall St target ($64.27)
- CAUTION: Recommendation downgraded due to -9.2% 5-day decline
Fair Price Analysis
30-Day Fair Range
$37.62 -
$51.45
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$28.00
Resistance Level
$50.70
Current Trend
Uptrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-8.26
Wall Street Target
$64.27
(+121.2%)
Share & Embed Analysis
Last updated: April 02, 2026 12:58 PM ET
Data refreshes hourly during market hours. Next update: 1:58 PM
Data refreshes hourly during market hours. Next update: 1:58 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MAZE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
14
Sells
Net
INSIDERS SELLING
Recent Transactions
Harold Bernstein
SELL
30000 shares
2026-03-10
Amy Bachrodt
SELL
5000 shares
2026-02-02
Harold Bernstein
SELL
15000 shares
2026-02-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 66 BUY |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$33 | 61 BUY |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$43 | 65 BUY |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$40 | 62 BUY |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$109 | 48 HOLD |
